The pathogen Acinetobacter baumannii can survive on hospital surfaces — without water — for months, an ability that has helped it become a leading cause of hospital-acquired infections. Now, a team of Vanderbilt researchers has […]
In a new study, Qiyun Zhu and his colleagues describe a new method for probing the microbiome in unprecedented detail. The technique provides greater simplicity and ease of use compared with existing approaches. Using the new technique, […]
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is excited to announce it has identified three therapeutic leads for the Company’s Immuno-Oncology program significantly earlier than expected. This will enable preclinical animal studies […]
Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announces the first international approval of a compassionate treatment with its phages, in Sweden. The Swedish Medical Products […]
Xbiome Inc., an industry leading AI driven microbiome therapeutics company, today announced that it has acquired the clinical-stage M201 program from Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus […]
New research from Cornell scientists is exploring how human genetics impacts functions of the gut microbiome, and is expanding awareness of the role human genetics plays in shaping the microbiome. The trillions of individual organisms […]
A research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Massachusetts Institute of Technology (MIT), using a synthetic biology approach, has developed an engineered live biotherapeutic product (eLBP) that, when […]
With 400 registered and 60 people on the waiting list, this edition of Probiota, the first in-person since 2020, broke all records. The event started with the best and only way it is meant to: […]
Microba Life Sciences (ASX:MAP), a precision microbiome science company, commenced trading on the Australian Securities Exchange (ASX) on April 4th following the completion of an initial public offering (IPO). The IPO raised $30.0 million and […]
Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the AMR Action Fund has joined an existing $41 million Series B round as a […]